This firm's average rating is Strong Buy from 1 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on VistaGen Therapeutics market sentiment investors' perception of the future value of VistaGen. Let us look at a few aspects of VistaGen technical analysis.
Using predictive
technical analysis, we can analyze different prices and returns patterns and
diagnose historical swings to determine the real value of VistaGen Therapeutics. In general, sophisticated investors focus on analyzing VistaGen Therapeutics stock price patterns and their correlations with different microeconomic environment and drivers. They apply predictive analytics to build VistaGen Therapeutics's daily price indicators and compare them against related drivers such as
momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional
technical analysis and
fundamental analysis, we attempt to find the most accurate representation of VistaGen Therapeutics's intrinsic value. In addition to deriving basic predictive indicators for VistaGen Therapeutics, many experienced traders also check how macroeconomic factors affect VistaGen Therapeutics price patterns. Please read more on our
technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed
many market ups and downs, anticipate that the market will even out over time. This tendency of VistaGen Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as VistaGen Therapeutics. Your research has to be compared to or analyzed against VistaGen Therapeutics' peers to derive any actionable benefits. When done correctly, VistaGen Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in VistaGen Therapeutics.
How does VistaGen Stands against Peers?
Analyzing VistaGen Therapeutics competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to VistaGen Therapeutics across multiple sectors and
thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be. Check out
VistaGen Therapeutics Competition DetailsVistaGen Therapeutics Gross Profit
VistaGen Therapeutics Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing VistaGen Therapeutics previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show VistaGen Therapeutics Gross Profit growth over the last 10 years. Please check VistaGen Therapeutics'
gross profit and other
fundamental indicators for more details.
Closer look at VistaGen Therapeutics Standard Deviation
VistaGen Therapeutics has current Standard Deviation of 7.7. The Standard Deviation is a measure of how spread out the prices or returns of an asset are on average. It is the most widely used risk indicator in the field of investing and finance. Standard Deviation is commonly used to measure confidence in statistical conclusions regarding certain equity instruments or portfolios of equities.
Standard deviation is applied to the annual rate of return of an investment to measure the investment's volatility. Standard deviation is also known as historical volatility and is used by investors as a gauge for the amount of expected market volatility. A large standard deviation usually indicates that the data points are far from the mean and a small standard deviation indicates that they are clustered closely around the mean.
Standard Deviation | = | SQRT(V) |
| = | 7.7 |
Let's now compare VistaGen Therapeutics Standard Deviation to its closest peers:
| VTGN | 7.700683805803809 |
| REGN | 2.0 |
| ALXN | 4.07 |
| WXXWY | 8.73 |
| IMMU | 12.24 |
VistaGen Therapeutics implied volatility may change after the rise
The skewness is down to 3.83 as of today. VistaGen Therapeutics is displaying above-average volatility over the selected time horizon. Investors should scrutinize VistaGen Therapeutics independently to ensure intended market timing strategies are aligned with expectations about VistaGen Therapeutics volatility.
Our Conclusion on VistaGen Therapeutics
Whereas few other entities under the biotechnology industry are still a bit expensive, VistaGen Therapeutics may offer a potential longer-term growth to institutional investors. On the whole, as of the 4th of January 2021, our analysis shows that VistaGen Therapeutics almost neglects market trends. The company is
undervalued and projects
low probability of distress for the next 2 years. However, our ongoing 30 days buy-hold-sell advice on the company is
Sell.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of VistaGen Therapeutics. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com